ArticleMolecular and clinical oncology2025
Enhanced efficacy of immune checkpoint inhibitors with OK-432 in malignant pleural mesothelioma: A case report.
Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant pleural mesothelioma (MPM) is a rare and highly aggressive cancer with limited treatment options and poor prognosis. Although immunotherapy with ipilimumab (IPI) and nivolumab (NIVO) has the potential to improve outcomes, disease progression, including recurrent pleural effusions, often occurs during or after the initial treatment. OK-432, an immunotherapeutic agent, is commonly used for pleurodesis to control malignant pleural effusions; however, its role in combination with immune checkpoint inhibitors (ICIs) remains underexplored. The present report describes 2 MPM cases in which patients initially responded to IPI and NIVO, but experienced disease progression. Following intrathoracic administration of OK-432, the patients were successfully rechallenged with ICI therapy. Both cases exhibited sustained disease control and resolution of pleural effusions. These findings suggested that OK-432 may modulate immune responses and potentially enhance the efficacy of ICIs. Further studies are warranted to validate the synergistic potential of OK-432 and ICIs in MPM and other thoracic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.